Rahul Rangan
Research Subjects
Rahul Rangan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amin Zakeri
Department of Translational Hematology & Oncology Research
1 shared publication - Anthony Tufaro
Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publication - Booki Min
Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611
1 shared publication - Cassandra Gilmour
Department of Translational Hematology & Oncology Research
1 shared publication - Dia Roy
Department of Translational Hematology & Oncology Research
1 shared publication - Elizabeth DeLaney
Department of Translational Hematology & Oncology Research
1 shared publication
Latest Publications
- Open Access
- 16 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint protein that impairs antitumor T cell responses. While broadly expressed on myeloid cells and T cells, the specific contribution of T cell–intrinsic VISTA to antitumor immunity remains undefined. This study investigated the phenotypic and functional consequences of T cell–specific VISTA deletion in tumor-specific CD8 + T cells. Single-cell transcriptomic analysis, TCR repertoire profiling, and flow cytometry revealed that loss of T cell–intrinsic VISTA enhanced early priming and short-term expansion of CD8 + T cells, yet this initial advantage failed to confer durable tumor control. Persistent dysfunction in VISTA-deficient T cells was in part driven by trans -VISTA on myeloid cells, while CTLA-4 upregulation further constrained T cell responses. T cell–intrinsic VISTA deficiency cooperated with CTLA-4 blockade to improve T cell survival and broaden TCR repertoire diversity, resulting in more robust tumor regression than CTLA-4 inhibition alone. A transcriptional signature enriched in VISTA-deficient cytotoxic T cells correlated with favorable outcomes in cancer patients treated with existing immune checkpoint inhibitors. These findings collectively define T cell–intrinsic mechanisms by which VISTA enforces T cell dysfunction and underscore its potential as both a therapeutic target and a biomarker of resistance to current immunotherapies.
- 16 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Open AccessT cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint protein that impairs antitumor T cell responses. While broadly expressed on myeloid cells and T cells, the specific contribution of T cell–intrinsic VISTA to antitumor immunity remains undefined. This study investigated the phenotypic and functional consequences of T cell–specific VISTA deletion in tumor-specific CD8 + T cells. Single-cell transcriptomic analysis, TCR repertoire profiling, and flow cytometry revealed that loss of T cell–intrinsic VISTA enhanced early priming and short-term expansion of CD8 + T cells, yet this initial advantage failed to confer durable tumor control. Persistent dysfunction in VISTA-deficient T cells was in part driven by trans -VISTA on myeloid cells, while CTLA-4 upregulation further constrained T cell responses. T cell–intrinsic VISTA deficiency cooperated with CTLA-4 blockade to improve T cell survival and broaden TCR repertoire diversity, resulting in more robust tumor regression than CTLA-4 inhibition alone. A transcriptional signature enriched in VISTA-deficient cytotoxic T cells correlated with favorable outcomes in cancer patients treated with existing immune checkpoint inhibitors. These findings collectively define T cell–intrinsic mechanisms by which VISTA enforces T cell dysfunction and underscore its potential as both a therapeutic target and a biomarker of resistance to current immunotherapies.